3D Morphometric Classifiers for Non-Invasive MMRD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting DNA mismatch repair deficiency (MMRD) in cancer cells are invasive, expensive, and lack concordance in data obtained using different sequencing platforms, making it difficult to predict patient response to immunotherapy effectively.
Innovation Solution
A method and system using optical tomography to develop morphometric classifiers that identify MMRD by analyzing structural biomarkers in 3D at a sub-micron scale, leveraging the Cell-CT™ platform for 3D cell imaging and morphometric genotyping.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biopsy-based MMRD detection methods are used, then detection accuracy is improved, but patient invasiveness and procedural complexity increase
Solution Approach 1:
The patent replaces mechanical/invasive biopsy procedures with optical detection methods. The optical tomography system uses light to detect morphometric changes in cells that indicate MMRD, eliminating the need for physical tissue sampling while maintaining diagnostic accuracy through non-invasive imaging of cellular structural biomarkers
Solution Approach 2:
The patent introduces optical tomography imaging as an intermediary method between invasive biopsy and MMRD detection. Instead of directly obtaining tissue samples, the system uses optical imaging to detect morphometric changes in cellular structures (nuclear morphology, chromatin organization) that serve as proxies for MMRD status, thereby mediating the detection process without direct tissue intervention
2Measurement precision
If next-generation sequencing (NGS) platforms are used for MMRD detection, then detection sensitivity is improved, but cost and technological complexity increase
Solution Approach 1:
The patent substitutes complex NGS sequencing platforms with optical tomography technology. Instead of using sophisticated molecular biology equipment to sequence DNA and detect mutations, the system employs optical imaging to detect morphometric changes in cellular structures that correlate with MMRD, replacing complex biochemical sequencing with simpler optical measurement
Solution Approach 2:
The patent changes the detection parameter from molecular genetic information (DNA sequences, mutations) to morphometric parameters (nuclear size, shape, chromatin organization). By measuring structural biomarkers through optical tomography rather than sequencing genetic material, the system achieves MMRD detection with reduced technological complexity while maintaining sensitivity
3Device complexity
If conventional 2D imaging is used for cell analysis, then device simplicity is maintained, but measurement precision and detection sensitivity decrease
Solution Approach 1:
The patent transitions from 2D imaging to 3D optical tomography to analyze cellular structures. The optical tomography system reconstructs three-dimensional images of cells and nuclei, enabling precise measurement of morphometric parameters in three dimensions. This dimensional enhancement provides comprehensive structural information while maintaining relative system simplicity through computational reconstruction from multiple 2D projections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive, cost-effective detection of MMRD, allowing for personalized immunotherapy treatment decisions and improved patient outcomes by identifying cells with early-stage cancer.
Implementation Method 1
a method and system for developing one or more morphometric classifiers to identify cells exhibiting DNA mismatch repair deficiency (MMRD) using a 3D optical tomography system
Data Source
AI summary
A method to develop one or more morphometric classifiers to identify a mismatch repair deficiency (MMRD). The method provides a non-invasive method of characterizing MMRD that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.